Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 70, Issue 12, Pages 3451-3460Publisher
SPRINGER
DOI: 10.1007/s00262-021-02936-1
Keywords
Ovarian cancer; Cancer vaccine; Cancer immunotherapy; CD27; Suppressive myeloid cells; MDSC
Categories
Funding
- Ovarian Cancer Research Alliance Grant [326870]
- Roswell Park Alliance Foundation
- NCI [P50CA159981-01A1, U01 CA233085-01A1, R01CA188900, R03CA223623, P30CA016056]
Ask authors/readers for more resources
Cancer immunotherapies have shown significant clinical responses in some ovarian cancer patients, but there is still a need to identify combination therapies to overcome limitations of single-agent treatments. A study using a pre-clinical model of aggressive ovarian cancer found that a heterologous prime/boost cancer vaccine combined with checkpoint blockade improved tumor control, with a focus on the essential role of CD8 + T cells in tumor regression.
Cancer immunotherapies have generated remarkable clinical responses for some patients with advanced/metastatic disease, prompting exploration of rational combination therapies to bolster anti-tumor immunity in patients with limited response or those who experience tumor progression following an initial response to immunotherapy. In contrast to other tumor indications, objective response rates to single-agent PD-1/PD-L1 blockade in ovarian cancer are limited, suggesting a need to identify combinatorial approaches that lead to tumor regression in a setting where checkpoint blockade alone is ineffective. Using a pre-clinical model of aggressive intraperitoneal ovarian cancer, we have previously reported on a heterologous prime/boost cancer vaccine that elicits robust anti-tumor immunity, prolongs survival of tumor-bearing mice, and which is further improved when combined with checkpoint blockade. As tumor control in this model is CD8 + T cell dependent, we reasoned that the prime/boost vaccine platform could be used to explore additional treatment combinations intended to bolster the effects of CD8 + T cells. Using whole tumor transcriptomic data, we identified candidate therapeutic targets anticipated to rationally combine with prime/boost vaccination. In the context of a highly effective cancer vaccine, CD27 agonism or antibody-mediated depletion of granulocytic cells each modestly increased tumor control following vaccination, with anti-PD-1 therapy further improving treatment efficacy. These findings support the use of immunotherapies with well-defined mechanisms(s) of action as a valuable platform for identifying candidate combination approaches for further therapeutic testing in ovarian cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available